AIM: To examine changes in biomarkers expressed in breast tumors in response to patient treatment with the polyamine synthesis inhibitor alpha-difluoromethylornithine (DFMO). PATIENTS AND METHODS: The expression of Ki-67 (MIB-1), matrix metalloproteinases (MMP) 2 and 9, urokinase-type plasminogen activator (uPA) were examined by immunohistochemistry in breast tissue specimens (controls: n=15, 13 evaluable, and DFMO group; n=27, 21 evaluable). Apoptosis was evaluated by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL). RESULTS: Significant increases in apoptosis, MMP-9 and uPA (tumor) were observed in 7 patients >or=50 years who received DFMO for >or=14 days relative to patients <50 years and/or who received <14 days of treatment (n=11). No other measured characteristics, including tumor estrogen and progesterone receptor status, hormone replacement therapy history, histopathological characteristics or tumor grade were correlated with these biomarker changes. CONCLUSION: Unexpected correlation of proapoptotic DFMO activity in postmenopausal women with breast cancer warrants further study.
AIM: To examine changes in biomarkers expressed in breast tumors in response to patient treatment with the polyamine synthesis inhibitor alpha-difluoromethylornithine (DFMO). PATIENTS AND METHODS: The expression of Ki-67 (MIB-1), matrix metalloproteinases (MMP) 2 and 9, urokinase-type plasminogen activator (uPA) were examined by immunohistochemistry in breast tissue specimens (controls: n=15, 13 evaluable, and DFMO group; n=27, 21 evaluable). Apoptosis was evaluated by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL). RESULTS: Significant increases in apoptosis, MMP-9 and uPA (tumor) were observed in 7 patients >or=50 years who received DFMO for >or=14 days relative to patients <50 years and/or who received <14 days of treatment (n=11). No other measured characteristics, including tumor estrogen and progesterone receptor status, hormone replacement therapy history, histopathological characteristics or tumor grade were correlated with these biomarker changes. CONCLUSION: Unexpected correlation of proapoptotic DFMO activity in postmenopausal women with breast cancer warrants further study.
Authors: Sarah M Kreul; Tom Havighurst; KyungMann Kim; Eneida A Mendonça; Gary S Wood; Stephen Snow; Abbey Borich; Ajit Verma; Howard H Bailey Journal: Cancer Prev Res (Phila) Date: 2012-10-11
Authors: Gaurav Kumar; Jagan Mohan R Patlolla; Venkateshwar Madka; Altaf Mohammed; Qian Li; Yuting Zhang; Laura Biddick; Anil Singh; Allison Gillaspy; Stanley Lightfoot; Vernon E Steele; Levy Kopelovich; Chinthalapally V Rao Journal: Am J Cancer Res Date: 2016-05-01 Impact factor: 6.166